Novo Nordisk's Drug Arsenal Expands with Pill Milestone and Deals, but Regulatory Fog Holds the Stock Down
Published on 06/06/2026 at 17:58 | Redaktion boerse-global.de
For all the clinical momentum building at Novo Nordisk — from a record-breaking oral Wegovy launch to fresh data for its next-generation obesity candidate — the Danish drugmaker's shares have barely budged. The stock ended last week at €37.27, a 4.57% decline (some data put the close at €37.35 and the weekly loss at 4.35%), leaving it nearly 47% below the June 2025 high and roughly 10% under its 200-day moving average. The disconnect between operational progress and market sentiment widens by the week.
The main weight on the equity is political. The Consolidated Appropriations Act 2026 and looming CMS negotiations over GLP-1 pricing in Medicare Part D have spooked investors into pricing in permanent margin erosion. Novo Nordisk itself projects revenue and operating profit to shrink by 5% to 13% this year, hit by expiring Semaglutide exclusivity in several markets and intensifying US price pressure. Against that backdrop, even a torrent of positive pipeline news has failed to reverse the stock's slide.
Wegovy’s Oral Version Surpasses Expectations
The strongest near-term commercial signal came from the oral formulation of Wegovy. Approved at the end of 2025, the once-daily pill had racked up 1.3 million prescriptions by the end of the first quarter. That tally has since crossed two million, suggesting the oral form is expanding the GLP-1 market rather than cannibalising the injectable version. Analysts note the speed of uptake is outstripping initial forecasts, which is critical as Novo faces competition from Eli Lilly’s Tirzepatid and the erosion of its patent position in India.
Combination Strategy Targets an Overlooked Population
Alongside the pill's success, the company has been quietly building a combination pipeline. In a clinical supply agreement disclosed via a US Securities and Exchange Commission filing, Novo Nordisk is providing Wegovy free of charge to Veru Inc. for a Phase 2b study called PLATEAU. The trial tests the oral androgen receptor modulator enobosarm alongside semaglutide in elderly obese patients, aiming to prevent muscle loss during weight reduction. Novo receives first negotiation rights for any future commercial combination products. The deal sent Veru’s shares soaring 167% on the announcement day, while Novo itself gained roughly 4% — insufficient to offset the week’s overall decline.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Zenagamtide Data Provides a Pipeline Boost
Internal development is also delivering. The dual GLP-1/amylin agonist zenagamtide (formerly Amycretin) achieved a mean weight loss of 14.6% in a Phase 2 study involving 262 type 2 diabetes patients, versus 2.1% for placebo. HbA1c dropped by 1.71 percentage points, and adverse events were mild to moderate — in line with the drug class. The company plans to launch Phase 3 in the second half of 2026. If successful, zenagamtide could ease Novo’s dependence on Wegovy and provide a second pillar in the GLP-1 franchise.
Early-Stage Programmes and Conference Season
Behind the scenes, two new Phase 1 candidates have entered the clinic. NNC0497-0040 began a randomised, quadruple-blind trial in May 2026, while NNC0113-5840, an injectable obesity therapy, was filed in April and is currently recruiting. Both are at the earliest safety stage, so clinical relevance remains years away.
The near-term catalyst is the R&D investor day scheduled for Sunday, 7 June, alongside the American Diabetes Association annual meeting in New Orleans. Novo plans to present 40 abstracts, including Phase 3 data for CagriSema — a fixed-dose combination of semaglutide and the experimental amylin analogue cagrilintide submitted for US approval in December 2025, with a decision expected in the fourth quarter. Mid-stage data for injectable zenagamtide will also be unveiled.
Modest Support from Buybacks and Analyst Restraint
The stock is being mechanically propped up by a buyback programme that runs until February 2027, targeting up to 11.2 billion Danish kroner in B-shares. As of late May, Novo had repurchased nearly 17.9 million shares at an average price of around DKK 263.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
On Wall Street, the analyst community remains cautious. Of 23 brokers covering the stock, 18 rate it a hold, four a buy, and one a sell. The average price target stands at $65.56. Goldman Sachs reaffirmed its hold rating on 3 June, reflecting the tug-of-war between strong pipeline and uncertain pricing.
The coming weeks will test whether clinical catalysts can overpower the political headwinds. The next earnings report is due 5 August, by which time CMS negotiations may have clarified — or deepened — the margin cloud hanging over Denmark's most valuable company.
Ad
Novo Nordisk Stock: New Analysis - 6 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
